These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20546266)

  • 41. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Haemoglobin A1c analysis in the management of patients with diabetes: from chaos to harmony.
    Berg AH; Sacks DB
    J Clin Pathol; 2008 Sep; 61(9):983-7. PubMed ID: 18755722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frequency of glycated hemoglobin monitoring was inversely associated with glycemic control of patients with Type 2 diabetes mellitus.
    Fu C; Ji L; Wang W; Luan R; Chen W; Zhan S; Xu B
    J Endocrinol Invest; 2012 Mar; 35(3):269-73. PubMed ID: 21606668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of an outpatient pharmacy clinical services program on adherence and clinical outcomes among patients with diabetes and/or coronary artery disease.
    Spence MM; Makarem AF; Reyes SL; Rosa LL; Nguyen C; Oyekan EA; Kiyohara AT
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1036-45. PubMed ID: 25278326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.
    Zoungas S; Chalmers J; Ninomiya T; Li Q; Cooper ME; Colagiuri S; Fulcher G; de Galan BE; Harrap S; Hamet P; Heller S; MacMahon S; Marre M; Poulter N; Travert F; Patel A; Neal B; Woodward M;
    Diabetologia; 2012 Mar; 55(3):636-43. PubMed ID: 22186981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
    Lewin A; Lipetz R; Wu J; Schwartz S
    Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Degree of control and delayed intensification of antihyperglycaemic treatment in type 2 diabetes mellitus patients in primary care in Spain.
    Conthe P; Mata M; Orozco D; Pajuelo F; Barreto CS; Anaya SF; Gomis R
    Diabetes Res Clin Pract; 2011 Jan; 91(1):108-14. PubMed ID: 21035225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
    Charpentier G; Halimi S;
    Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes.
    Harris MI;
    Diabetes Care; 2001 Jun; 24(6):979-82. PubMed ID: 11375356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of a structured behavioral intervention on poorly controlled diabetes: a randomized controlled trial.
    Weinger K; Beverly EA; Lee Y; Sitnokov L; Ganda OP; Caballero AE
    Arch Intern Med; 2011 Dec; 171(22):1990-9. PubMed ID: 21986346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of an 'implementation intention' intervention on adherence to oral anti-diabetic medication in Brazilians with type 2 diabetes.
    Trevisan DD; São-João T; Cornélio M; Jannuzzi F; de Sousa MR; Rodrigues R; Lima MH
    Patient Educ Couns; 2020 Mar; 103(3):582-588. PubMed ID: 31630899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes.
    Albarracin CA; Fuqua BC; Evans JL; Goldfine ID
    Diabetes Metab Res Rev; 2008; 24(1):41-51. PubMed ID: 17506119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hemoglobin Glycosylation Index is not related with blood glucose.
    Merino-Torres JF; Fajardo-Montañana C; Ferrer-García JC; Piñón-Sellés F
    J Diabetes Complications; 2003; 17(5):249-53. PubMed ID: 12954152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Changes in weight and diabetes compensation (HbA(1c)) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBY-I study (observations lasting 3 to 12 months)].
    Perusicová J; Haladová I; Pit'hová P; Acsová D; Belobrádková J; Belzová A; Berková K; Dolezalová B; Dvoráková H; Hejnicová K; Hudcová M; Kallmünzerová D; Krejsová Z; Markofová G; Müllerová H; Owen K; Pelikánová M; Raclavská L; Racická E; Skarpová O; Váchová A; Veselá A; Vyoralos J; Broz J; Edelsberger T; Honka M; Hrdina T; Chmura P; Tosovský J
    Vnitr Lek; 2013 Mar; 59(3):165-71. PubMed ID: 23713182
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Refill adherence to oral antihyperglycaemic drugs in Sweden.
    Haupt D; Weitoft GR; Nilsson JL
    Acta Diabetol; 2009 Sep; 46(3):203-8. PubMed ID: 19023514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
    Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
    Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adherence to oral antidiabetic medications in the pediatric population with type 2 diabetes: a retrospective database analysis.
    Adeyemi AO; Rascati KL; Lawson KA; Strassels SA
    Clin Ther; 2012 Mar; 34(3):712-9. PubMed ID: 22381712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.